Elevance Health Stock News

Elevance Health is a strong buy despite a 30% stock decline, due to its solid fundamentals and market position in the health insurance industry. The company benefits from secular trends like an aging population and increased life expectancy, driving long-term demand for healthcare services. Key risks include rising healthcare costs and a shrinking Medicaid member base, impacting margins and fre...

Investing in blue-chip stocks at 52-week lows can potentially yield significant returns if fundamentals are strong. Avoid value traps by focusing on companies with solid fundamentals, like Elevance Health, Becton, Dickinson, LyondellBasell, Rogers Communications and Rexford Industrial Realty. These companies offer a 3.7% yield and a 27% discount to fair value, and they have historically outperf...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey.

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a bipartisan group of lawmakers were set to introduce legislation to break up pharmacy-benefit managers.

Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration.

Thompson's death sparked a wide social media conversation over frustrations with navigating the US health insurance system.

Shares of health insurance companies including UnitedHealth Group continued to fall on Friday, two days after Brian Thompson, the CEO of the company's health insurance unit, was fatally shot outside a Manhattan hotel by a gunman lying in wait.